Dorzopt, eye drops 2% 5 ml 3 pcs

Elevated intraocular pressure, Glaucoma

Open-angle (including secondary) glaucoma;

Pseudoexfoliative glaucoma;

Ophthalmohypertension.

Active ingredient

Composition

Composition: per 1.0 ml of the drug:

The active ingredient:

dorzolamide hydrochloride in terms of dorzolamide 20.00 mg;

Auxiliary substances:

hyethylose,

mannitol,

citric acid monohydrate,

sodium hydroxide,

benzalkonium chloride,

purified water.

Description:

a clear, colorless solution.

How to take, the dosage

Push 1 drop into the affected eye 3 times a day;

In combination with beta-adrenoblockers for local use – 1 drop 2 times a day.

If more than one topical ophthalmic drug is used in treatment, it must be administered at 10-minute intervals.

Interaction

Antiglaucoma drugs (beta-adrenoblockers, pilocarpine, dipivefrine, carbachol) enhance the effect of dorzolamide.
Simultaneous use with acetazolamide increases the risk of systemic side effects.

Toxicity may be increased when taking high doses of acetylsalicylic acid.

Special Instructions

The preservative in dorzolamide drops (benzalkonium chloride) may be absorbed by soft contact lenses, causing eye irritation and toxic effects. The drug is used only after removal of contact lenses.

Please wear contact lenses not earlier than 15 minutes after the injection. The K+, serum electrolytes and blood pH should be monitored.
Older patients may become more sensitive to dorzolamide (dose reduction is required).

When using during the treatment it is necessary to observe caution while driving motor transport and engaging in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.

Contraindications

Hypersensitivity to any component, chronic renal insufficiency (creatinine clearance less than 30 ml/min), hyperchloremic acidosis, children under 18 years of age, pregnancy, lactation, oral use of carboangidrase inhibitors.

Side effects

Local: Burning, paresthesias, itching in eyes, lacrimation, blurred vision, eyelid irritation and edema, conjunctivitis, superficial pitting keratitis, blepharitis, photophobia;

Rarely, iridocyclitis, increased corneal thickness, allergic reactions; eye hypotonia, retinal detachment in patients after anti-glaucoma surgery.

Systemic: bitterness in the mouth, nausea, headache, asthenia, nephrourolithiasis, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome), agranulocytosis, aplastic anemia, skin rash.

Overdose

Symptoms: water-electrolyte metabolism disorders, acidosis, central nervous system (CNS) disorders.

Treatment: symptomatic. Control of electrolyte levels (especially K+) and blood pH.

Similarities